• Users Online: 79
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Referee Resource Subscribe
Year : 2018  |  Volume : 5  |  Issue : 1  |  Page : 4-8

Adjuvant therapy in poor ovarian response – Where do we stand?

Consultant, Department of IVF & Reproductive Biology, Indraprastha Apollo Hospital, New Delhi, India

Correspondence Address:
Rupali Goyal
A-18, ‘Malhaar Kunj’, Neb Valley Neb Sarai, New Delhi 110068
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/fsr.fsr_31_18

Rights and Permissions

In the current era, there is an ever increasing incidence of poor ovarian response. Many strategies have been studied and hypothesized for the management. Androgens have been widely used and studies in the management of Poor ovarian response. The two prime androgens used in poor ovarian response are Dehydroepiandrosterone [DHEA], Androstenadione and testosterone. Use of Growth hormone, recombinant luteinizing Hormone and vasoactive substances have been analyzed based on the current evidence.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded273    
    Comments [Add]    

Recommend this journal